VIMTALABS Stock Overview
Vimta Labs Limited provides contract research and testing services in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Vimta Labs Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹433.70 |
| 52 Week High | ₹623.15 |
| 52 Week Low | ₹291.85 |
| Beta | 0.66 |
| 1 Month Change | 4.81% |
| 3 Month Change | -25.24% |
| 1 Year Change | 6.14% |
| 3 Year Change | 155.95% |
| 5 Year Change | 63.23% |
| Change since IPO | -52.26% |
Recent News & Updates
Recent updates
If EPS Growth Is Important To You, Vimta Labs (NSE:VIMTALABS) Presents An Opportunity
Jul 14
Vimta Labs (NSE:VIMTALABS) Has Announced A Dividend Of ₹2.00
Jun 03Vimta Labs' (NSE:VIMTALABS) Dividend Will Be ₹2.00
May 06A Look At The Intrinsic Value Of Vimta Labs Limited (NSE:VIMTALABS)
Dec 07Here's Why We Think Vimta Labs (NSE:VIMTALABS) Might Deserve Your Attention Today
Nov 06Vimta Labs (NSE:VIMTALABS) Is Due To Pay A Dividend Of ₹2.00
Jun 02Does Vimta Labs (NSE:VIMTALABS) Deserve A Spot On Your Watchlist?
Dec 06Here's Why Vimta Labs (NSE:VIMTALABS) Can Manage Its Debt Responsibly
Oct 27We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Vimta Labs Limited's (NSE:VIMTALABS) CEO For Now
Jun 29Does Vimta Labs (NSE:VIMTALABS) Have A Healthy Balance Sheet?
Jun 19Here's Why Vimta Labs (NSE:VIMTALABS) Can Manage Its Debt Responsibly
Mar 09Vimta Labs Limited's (NSE:VIMTALABS) Stock Is Going Strong: Have Financials A Role To Play?
Jan 20Did You Miss Vimta Labs' (NSE:VIMTALABS) 87% Share Price Gain?
Dec 30Does Vimta Labs (NSE:VIMTALABS) Have A Healthy Balance Sheet?
Dec 09
Here's What We Learned About The CEO Pay At Vimta Labs Limited (NSE:VIMTALABS)
Nov 17Vimta Labs Limited's (NSE:VIMTALABS) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Oct 21Here's Why Vimta Labs (NSE:VIMTALABS) Has A Meaningful Debt Burden
Sep 10Vimta Labs Limited's (NSE:VIMTALABS) Price Is Out Of Tune With Earnings
Aug 05Vimta Labs Limited's (NSE:VIMTALABS) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Jul 14Shareholder Returns
| VIMTALABS | IN Life Sciences | IN Market | |
|---|---|---|---|
| 7D | 4.4% | -2.9% | 3.3% |
| 1Y | 6.1% | 14.0% | 19.1% |
Return vs Industry: VIMTALABS underperformed the Indian Life Sciences industry which returned 14% over the past year.
Return vs Market: VIMTALABS underperformed the Indian Market which returned 19.1% over the past year.
Price Volatility
| VIMTALABS volatility | |
|---|---|
| VIMTALABS Average Weekly Movement | 5.6% |
| Life Sciences Industry Average Movement | 5.3% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in IN Market | 8.7% |
| 10% least volatile stocks in IN Market | 3.4% |
Stable Share Price: VIMTALABS is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: VIMTALABS's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 1,368 | Harita Vasireddi | https://vimta.com |
Vimta Labs Limited provides contract research and testing services in India and internationally. It offers product discovery/development, post approval/marketing, preclinical/early development/study, clinical research and development, drug life cycle management support, bioanalytical, analytical, central lab, genetically modified organisms testing, clinical diagnostics, environment testing, preclinical research and testing, food testing and analytical development, and EMI/EMC testing services, as well as IND/505 (b)(2) enabling/studies; IVPT, IVRT, and IVBE studies; and testing services for dioxins and furans, trace heavy metals, label claims, radioactive isotopes, vitamins and minerals, packaging, and shelf life. The company provides solutions to agriculture, electricals and electronics, medical devices, speciality chemicals, biologics and biosimilars, environment, health and safety, nutraceuticals, water and beverages, crop care, food, packaging, clinical diagnostics, home and personal care, and pharmaceuticals industries.
Vimta Labs Limited Fundamentals Summary
| VIMTALABS fundamental statistics | |
|---|---|
| Market Cap | ₹9.63b |
| Earnings (TTM) | ₹414.50m |
| Revenue (TTM) | ₹3.17b |
23.2x
P/E Ratio3.0x
P/S RatioIs VIMTALABS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIMTALABS income statement (TTM) | |
|---|---|
| Revenue | ₹3.17b |
| Cost of Revenue | ₹898.95m |
| Gross Profit | ₹2.27b |
| Other Expenses | ₹1.86b |
| Earnings | ₹414.50m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Feb 14, 2024
| Earnings per share (EPS) | 18.70 |
| Gross Margin | 71.64% |
| Net Profit Margin | 13.08% |
| Debt/Equity Ratio | 6.5% |
How did VIMTALABS perform over the long term?
See historical performance and comparison